Is exclusive Skp2 targeting always beneficial in cancer therapy?
Koutsami
Marilena
M
Velimezi
Georgia
G
Kotsinas
Athanassios
A
Evangelou
Konstantinos
K
Papavassiliou
Athanassios G
AG
Kittas
Christos
C
Gorgoulis
Vassilis G
VG
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D050760:Cyclin-Dependent Kinase Inhibitor p27 / Q000235:genetics / Q000502:physiology; D016503:Drug Delivery Systems; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D009154:Mutation / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D034741:RNA, Small Interfering / Q000627:therapeutic use; D044786:S-Phase Kinase-Associated Proteins / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D034741:RNA, Small Interfering; D044786:S-Phase Kinase-Associated Proteins; D050760:Cyclin-Dependent Kinase Inhibitor p27